Vaccination has been shown to be a successful medical innovation in the fight against infectious diseases. Peptide subunit vaccines utilises selected microbial fragments and were developed to address the toxicity related issues associated with conventional vaccines (1). Peptide antigen, on the other hand, are poorly immunogenic and it would require the use of an adjuvant to enhance the immunogenicity and provide long-term protective immunity (2). Lipids have been known to act as an adjuvant once conjugated to the antigen for peptide subunit vaccines. Moreover, lipidation assists in peptide vaccine delivery to increase bioavailability, chemical stability, and protection against enzymatic degradation (3). To develop the vaccine candidates, peptide-based subunit vaccine strategy was used to incorporate B-cell epitope (J8, derived from GAS surface M protein), universal T-cell helper epitope (P25, derived from fusion protein of the morbillivirus canine distemper virus) and the lipopeptide adjuvants (LCPs, antimicrobial peptides and polyHAAs) as a physical mixture. The series of adjuvants and antigen were successfully synthesised through Solid Phase Peptide Synthesis (SPPS) with high yield and purity. Additionally, we assessed the structural characteristics of the physical mixture of the adjuvant and the antigen through 1) dynamic light scattering (DLS) and found that the mixture could self-assemble into stable nanoparticles ranging in size from 100 nm to 1000 nm and 2) circular dichroism (CD) and discovered that the lipopeptide adjuvant promote helicity of the antigen which is necessary for the antigen to induce immune response against GAS. In addition, in vivo evaluation of the vaccine candidates revealed that the conjugated construct was more efficient. In comparison to the other lipopeptides, we were able to discover one lipopeptide with promising adjuvanting properties, which evoked higher J8-specific IgG titers when in a physical mixture with the antigen.